IPG-023

N/A

Report date: 2024/03/18 10:43:08
NME

Base Information

Drug NameIPG-023
Drug Alias NameIPG-023IPG023
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNAD(+) hydrolase SARM1 inhibitors
TargetsNAD(+) hydrolase SARM1
Therapy Area/IndicationsNeurodegenerative Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Immunophage Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Immunophage Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsNeurodegenerative Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A